OACCFinancial Services · Shell CompaniesOACC Stock Forecast: Oaktree Acquisition Corp. III Life Sciences Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 15 Oct 2026 — in the upper half.
OACC stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Oaktree Acquisition Corp. III Life Sciences on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (91): The share price has been relatively steady.
Growth (23): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
OACC stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on OACC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. OACC appears on the weeks it earns a place.
OACC vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 15 Oct 2026, Oaktree Acquisition Corp. III Life Sciences returned +1.0% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
OACC analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Oaktree Acquisition Corp. III Life Sciences (OACC) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 38.0×
- Price / sales
- —
- Price / book
- 1.3×
- EV / EBITDA
- −218.0×
Cheaper than 20% of US stocks
Cheaper than 59% of US stocks
Cheaper than 98% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- −14.4%
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 24% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
- Return on equity
- 3.7%
- Return on assets
- 3.6%
- Dividend yield
- 0.0%
Higher than 51% of US stocks
Higher than 69% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Oaktree Acquisition Corp. III Life Sciences (OACC) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oaktree Acquisition Corp. III Life Sciences has a market value of $261.8M and an enterprise value of $260.6M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: $6.8M.
Free cash flow in the twelve months to 30 June 2026: −$456K.
Trailing P/E: 38.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Oaktree Acquisition Corp. III Life Sciences employs 0 people.
Data provided by Twelve Data
OACC vs competitors
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| OACCOaktree Acquisition Corp. III Life Sciences | $261.8M | 52 |
| ATIIArchimedes Tech SPAC Partners II Co. | $262.2M | 32 |
| NTWONewbury Street II Acquisition Corp. | $260.9M | 50 |
| TRGSTRG Latin America Acquisitions Corp. | $263.7M | 10 |
| DMAADrugs Made In America Acquisition Corp. | $263.9M | 73 |
| CATLCatalyst Acquisition Corp. | $265.4M | 5 |
| VNMEVendome Acquisition Corp. I | $257.8M | 49 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oaktree Acquisition Corp. III Life Sciences — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about OACC stock
How does Ticker Nerd's model rank OACC?
As at 15 Oct 2026, Oaktree Acquisition Corp. III Life Sciences ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (91 of 100).
What is the OACC stock forecast for 2030?
No analyst covering Oaktree Acquisition Corp. III Life Sciences publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for OACC are extrapolating price history, which says nothing about the business.
How has OACC stock performed over the past year?
Oaktree Acquisition Corp. III Life Sciences returned +1.0% over the 12 months to 15 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oaktree Acquisition Corp. III Life Sciences do?
Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company focused on identifying and completing a business combination in the life sciences sector.
About Oaktree Acquisition Corp. III Life Sciences.
Oaktree Acquisition Corp. III Life Sciences is a special purpose acquisition company focused on identifying and completing a business combination in the life sciences sector. Oaktree Acquisition Corp. III Life Sciences currently serves as a blank check vehicle, with no significant commercial operations, and is structured to pursue merger, share exchange, asset acquisition, stock purchase, reorganization, or similar transactions. Its stated investment focus includes businesses in biopharmaceuticals, medical devices, diagnostics, and specialized healthcare services, with an emphasis on opportunities in North America and Europe. The company’s role in the market is to provide a public capital structure that can be used to bring a private operating company into the public markets through a transaction approved by shareholders. Oaktree Acquisition Corp. III Life Sciences is based in Los Angeles, California.
CEO Mr. Zaid Pardesi · United States · https://www.oaktreeacquisitioncorp.com/oac-iii